Clarithromycin: Difference between revisions
(prior error) |
No edit summary |
||
| Line 29: | Line 29: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 3-4 hours (increased with dosage increase)<ref>Ferrero JL, Bopp BA, Marsh KC, et al. Metabolism and Disposition of Clarithromycin in Man. Drug Metab Dispos. 1990;18(4):441–446. [PubMed 1976065]</ref> | ||
*Metabolism: | *Metabolism: hepatic (rapid first-pass metabolism) | ||
*Excretion: | *Excretion: renal | ||
*Mechanism of Action: | *Mechanism of Action: interferes with bacterial protein synthesis by binding to a component of the 50S subunit | ||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ||
Revision as of 08:56, 8 August 2015
General
- Type: bacteriostatic
- Dosage Forms:
- Common Trade Names: Biaxin
Adult Dosing
Pediatric Dosing
Special Populations
- Pregnancy:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
- Liver disease
- Renal disease
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: 3-4 hours (increased with dosage increase)[1]
- Metabolism: hepatic (rapid first-pass metabolism)
- Excretion: renal
- Mechanism of Action: interferes with bacterial protein synthesis by binding to a component of the 50S subunit
Antibiotic Sensitivities[2]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia